Multipotent mesenchymal stromal cells in rheumatoid arthritis and systemic lupus erythematosus; from a leading role in pathogenesis to potential therapeutic saviors?

El-Jawhari, J.J. ORCID: 0000-0002-0580-4492, El-Sherbiny, Y. ORCID: 0000-0003-4791-3475, McGonagle, D. and Jones, E., 2021. Multipotent mesenchymal stromal cells in rheumatoid arthritis and systemic lupus erythematosus; from a leading role in pathogenesis to potential therapeutic saviors? Frontiers in Immunology, 12: 643170. ISSN 1664-3224

[img]
Preview
Text
1429702_a1675_El-Sherbiny.pdf - Published version

Download (1MB) | Preview

Abstract

The pathogenesis of the autoimmune rheumatological diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) is complex with the involvement of several immune cell populations spanning both innate and adaptive immunity including different T-lymphocyte subsets and monocyte/macrophage lineage cells. Despite therapeutic advances in RA and SLE, some patients have persistent and stubbornly refractory disease. Herein, we discuss stromal cells' dual role, including multipotent mesenchymal stromal cells (MSCs) also used to be known as mesenchymal stem cells as potential protagonists in RA and SLE pathology and as potential therapeutic vehicles. Joint MSCs from different niches may exhibit prominent pro-inflammatory effects in experimental RA models directly contributing to cartilage damage. These stromal cells may also be key regulators of the immune system in SLE. Despite these pro-inflammatory roles, MSCs may be immunomodulatory and have potential therapeutic value to modulate immune responses favorably in these autoimmune conditions. In this review, the complex role and interactions between MSCs and the haematopoietically derived immune cells in RA and SLE are discussed. The harnessing of MSC immunomodulatory effects by contact-dependent and independent mechanisms, including MSC secretome and extracellular vesicles, is discussed in relation to RA and SLE considering the stromal immune microenvironment in the diseased joints. Data from translational studies employing MSC infusion therapy against inflammation in other settings are contextualized relative to the rheumatological setting. Although safety and proof of concept studies exist in RA and SLE supporting experimental and laboratory data, robust phase 3 clinical trial data in therapy-resistant RA and SLE is still lacking.

Item Type: Journal article
Publication Title: Frontiers in Immunology
Creators: El-Jawhari, J.J., El-Sherbiny, Y., McGonagle, D. and Jones, E.
Publisher: Frontiers Media SA
Date: 24 February 2021
Volume: 12
ISSN: 1664-3224
Identifiers:
NumberType
10.3389/fimmu.2021.643170DOI
1429702Other
Rights: © 2021 El-Jawhari, El-Sherbiny, McGonagle and Jones. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Divisions: Schools > School of Science and Technology
Record created by: Jeremy Silvester
Date Added: 08 Apr 2021 13:07
Last Modified: 03 Jun 2021 13:03
URI: http://irep.ntu.ac.uk/id/eprint/42674

Actions (login required)

Edit View Edit View

Views

Views per month over past year

Downloads

Downloads per month over past year